Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | PGD | P52209 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8653297 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL8652316 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7152465 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL18040638 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7145527 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7148849 | 1.00 | TDP1 (0.73) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7150927 | 0.98 | TDP1 (0.77) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7150930 | 0.98 | TDP1 (0.77) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7155212 | 0.98 | TDP1 (0.77) | TDP1POLBMAPK1ABCB1PGD | |
| SCHEMBL7155217 | 0.98 | TDP1 (0.77) | TDP1POLBMAPK1ABCB1PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2024211999-A9 | EXTRACELLULAR HSP90 (EHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2025-01-16 | — | — | WO | disclosed |
| CN-119019476-A | Process for producing C-arylalkoxyglycoside derivative and other compounds | 株式会社德山 | 2024-11-26 | — | — | CN | disclosed |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024211999-A1 | EXTRACELLULAR HSP90 (EHSP90)-TARGETED RADIOPHARMACEUTICALS AND USE THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2024-10-17 | — | — | WO | disclosed |
| CN-118546061-A | Method for producing acid chloride derivative and method for producing ketone derivative | 株式会社德山 | 2024-08-27 | — | — | CN | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-0670677-A1 | POTENTIATOR OF $i(BACILLUS) PESTICIDAL ACTIVITY | ABBOTT LABORATORIES (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0493064-B1 | Deacetylcolchicine derivatives | OHGEN RESEARCH LAB LTD (JP) | 1995-02-15 | — | — | EP | disclosed |
| WO-1994009630-A1 | POTENTIATOR OF BACILLUS PESTICIDAL ACTIVITY | NOVO NORDISK ENTOTECH, INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5220002-A | Antitumor agents | OHGEN RESEARCH LABORATORIES, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0493064-A1 | Deacetylcolchicine derivatives | OHGEN RESEARCH LABORATORIES LTD., (JP) | 1992-07-01 | — | — | EP | disclosed |
| EP-0136012-B1 | CYTOSTATIC PLATINUM COMPLEXES | Kidani, Yoshinori (JP) | 1989-04-19 | — | — | EP | disclosed |
| US-4710577-A | Cytostatic platinum organic complexes | YOSHINORI KIDANI (JP) | 1987-12-01 | — | — | US | disclosed |
| EP-0207202-A1 | Anti-tumor platinum complexes | Kidani, Yoshinori (JP) | 1987-01-07 | — | — | EP | disclosed |
| US-4567285-A | ANTITUMOR AGENTS | YOSHINORI KIDANI (JP) | 1986-01-28 | — | — | US | disclosed |
| EP-0136012-A1 | Cytostatic platinum complexes | Kidani, Yoshinori (JP) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | TDP1 4630/4885POLB 3894/4885MAPK1 2648/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | TDP1 4630/4885POLB 3894/4885MAPK1 2648/4885 |
| US-20240366590-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | TDP1 4630/4885POLB 3894/4885MAPK1 2648/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | TDP1 4630/4885POLB 3894/4885MAPK1 2648/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | TDP1 4630/4885POLB 3894/4885MAPK1 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.